Search results for "BOS"

showing 10 items of 3713 documents

Field and microcosm experiments to evaluate the effects of agricultural Cu treatment on the density and genetic structure of microbial communities in…

2006

The effects of Cu amendment on indigenous soil microorganisms were investigated in two soils, a calcareous silty clay (Ep) and a sandy soil (Au), by means of a 1-year field experiment and a two-month microcosm incubation. Cu was added as 'Bordeaux mixture' [CuSO(4), Ca(OH)(2)] at the standard rate used in viticulture (B1=16 kg Cu kg(-1) soil) and at a higher level of contamination (B3=48 kg Cu ha(-1) soil). More extractable Cu was observed in sandy soil (Au) than in silty soil (Ep). Furthermore, total Cu and Cu-EDTA declined with time in Au soil, whereas they remained stable in Ep soil. Quantitative modifications of the microflora were assessed by C-biomass measurements and qualitative modi…

2. Zero hungerEcologySoil testRibosomal Intergenic Spacer analysisFungal genetics04 agricultural and veterinary sciences010501 environmental sciencesBiologycomplex mixtures01 natural sciencesApplied Microbiology and BiotechnologyMicrobiologyMicrobial population biologyEnvironmental chemistrySoil waterBotany040103 agronomy & agriculture0401 agriculture forestry and fisheriesMicrocosmSoil microbiologyCalcareous0105 earth and related environmental sciencesFEMS Microbiology Ecology
researchProduct

Plasma Antithrombin Values Are Significantly Decreased in Coronavirus Disease 2019 (COVID-19) Patients with Severe Illness

2020

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Plasma AntithrombinSeverity of Illness IndexAntithrombinsCoronavirus Disease 2019medicineHumansThrombophiliaProspective StudiesPlasma Antithrombin Coronavirus Disease 2019 COVID-19business.industryHeparinSARS-CoV-2AntithrombinAnticoagulantsCOVID-19ThrombosisHematologyDisseminated Intravascular CoagulationVirologyCross-Sectional StudiesbusinessCardiology and Cardiovascular Medicinemedicine.drug
researchProduct

Invited commentary to: ADAMTS13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19 by T…

2021

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Letter to the Editors-in-ChiefHematologyAbnormal distributionVirologyVon Willebrand factor multimersADAMTS13Thrombosis ResearchMedicineIn patientbusinessThrombosis Research
researchProduct

The Millennial Generation of Thrombosis and Hemostasis

2020

2019-20 coronavirus outbreakHemostasisCoronavirus disease 2019 (COVID-19)business.industry10031 Clinic for AngiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2720 Hematology610 Medicine & healthThrombosisHematologyBioinformaticsmedicine.diseaseThrombosisHemostasisMedicineHumansbusinessHämostaseologie
researchProduct

Atypical thrombosis associated with VaxZevria (R) (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres

2021

The current COVID-19 pandemic is an exceptional health situation including for drug use. As there was no known effective drug for COVID-19 at the beginning of the pandemic, different candidates were proposed. In this short article, we present the French public pharmacovigilance activities during this health crisis. Although COVID-19 is a confounding factor per se, owing to its potential for multi-organ damage including the heart and kidney, the quality of the transmitted data in adverse drug reaction reports, the timeliness of feedback from clinicians, and the real-time pharmacological and medical analysis by the French network of the regional pharmacovigilance centers made it possible to s…

2019-20 coronavirus outbreakTime FactorsCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[SDV]Life Sciences [q-bio]Letter to EditorAntiviral AgentsPharmacovigilancePharmacovigilancemedicineAdverse Drug Reaction Reporting SystemsHumansPharmacology (medical)PandemicsComputingMilieux_MISCELLANEOUSCovid-19 vaccineSARS-CoV-2business.industryCOVID-19VaxZevria®medicine.diseaseAtypical thrombosisThrombosisVirology[SDV] Life Sciences [q-bio]Anti-PF4 antibodiesFrancebusinessThrombopenia
researchProduct

"Table 12: Cross-section limits lepton specific tanb 1" of "Search for a heavy Higgs boson decaying into a $Z$ boson and another heavy Higgs boson in…

2018

The cross section times BR(A->ZH) times BR(H->bb) limits for an A boson in the lepton specific, tanbeta 1, 2HDM. For each signal point, characterised by the mass pair (mA, mH), two limits are provided, the observed and the expected. The correct width as predicted by this particular parameter choice of the 2HDM is used. For lepton specific only gluon-gluon fusion is used and the nb=2 category only.

2HDMHIGGS --> BQ BQBAR13000.0CLSHigh Energy Physics::Phenomenologycross section limitsZ0 --> MU+ MU-Z0 --> E+ E-P P --> HIGGSgluon-gluon fusionHigh Energy Physics::ExperimentHiggs boson productionHIGGS --> Z0 HIGGSgluon fusion
researchProduct

"Table 14: Cross-section limits lepton specific tanb 3" of "Search for a heavy Higgs boson decaying into a $Z$ boson and another heavy Higgs boson in…

2018

The cross section times BR(A->ZH) times BR(H->bb) limits for an A boson in the lepton specific, tanbeta 3, 2HDM. For each signal point, characterised by the mass pair (mA, mH), two limits are provided, the observed and the expected. The correct width as predicted by this particular parameter choice of the 2HDM is used. For lepton specific only gluon-gluon fusion is used and the nb=2 category only.

2HDMHIGGS --> BQ BQBAR13000.0CLSHigh Energy Physics::Phenomenologycross section limitsZ0 --> MU+ MU-Z0 --> E+ E-P P --> HIGGSgluon-gluon fusionHigh Energy Physics::ExperimentHiggs boson productionHIGGS --> Z0 HIGGSgluon fusion
researchProduct

"Table 13: Cross-section limits lepton specific tanb 2" of "Search for a heavy Higgs boson decaying into a $Z$ boson and another heavy Higgs boson in…

2018

The cross section times BR(A->ZH) times BR(H->bb) limits for an A boson in the lepton specific, tanbeta 2, 2HDM. For each signal point, characterised by the mass pair (mA, mH), two limits are provided, the observed and the expected. The correct width as predicted by this particular parameter choice of the 2HDM is used. For lepton specific only gluon-gluon fusion is used and the nb=2 category only.

2HDMHIGGS --> BQ BQBAR13000.0CLSHigh Energy Physics::Phenomenologycross section limitsZ0 --> MU+ MU-Z0 --> E+ E-P P --> HIGGSgluon-gluon fusionHigh Energy Physics::ExperimentHiggs boson productionHIGGS --> Z0 HIGGSgluon fusion
researchProduct

Baltu filoloģija, 23. sēj., Nr.1

2014

2nd Joint Conference on Baltic and Scandinavian StudiesPalīgteikumu morfosintaktiska struktūraSeminārs "Latviešu raksti un raksti Latvijā 16.-19. gadsimtā – pētniecības aktualitātes un problēmas"LU Akadēmiskais apgāds 2013." [Recenzija par "Veisbergs Andrejs (red.). Latviešu valoda. Rīga]Ērģemes evaņģēliski luteriskās draudzes Metriku grāmatasLithuanian grammarSecondary Resultative Predicates in LithuanianLatviešu valodas izloksnesMokslo ir enciklopedijų leidybos centras 2013." [Recenzija par "Mažiulis Vytautas. Prūsų kalbos etimologijos žodynas. Antrasis pataisytas ir papildytas leidimas. Vilnius]
researchProduct

Synthesis of Rosmarinic Acid Amides as Antioxidative and Hypoglycemic Agents

2019

Type 2 diabetes mellitus (T2DM) is an important metabolic disorder for which there is an urgent need for new antidiabetic drugs. α-Glucosidase inhibition is an established protocol for T2DM therapy. Because hyperglycemia causes oxidative tissue damage, the development of agents with both α-glucosidase inhibition and antioxidant activity from natural or natural-derived polyphenols such derivatives of rosmarinic acid (RA) represents an attractive therapeutic option. We report a study on amides 1-10 derived from RA and their evaluation for yeast α-glucosidase inhibition and antioxidant activity (DPPH and ORAC tests). All amides showed higher inhibitory activity than that of RA, were by far mor…

3003DrugAntioxidantDPPHProton Magnetic Resonance Spectroscopymedia_common.quotation_subjectmedicine.medical_treatmentPharmaceutical ScienceOxidative phosphorylationPharmacologyDepsides01 natural sciencesAntioxidantsAnalytical Chemistrychemistry.chemical_compoundDrug DiscoverymedicineHypoglycemic AgentsSettore BIO/15 - Biologia FarmaceuticaCarbon-13 Magnetic Resonance SpectroscopyIC50media_commonAcarbosePharmacology010405 organic chemistrydiabetes mellituDrug Discovery3003 Pharmaceutical ScienceRosmarinic acidOrganic ChemistrySettore CHIM/06 - Chimica OrganicaComplementary and Alternative Medicine2708 DermatologyAmidesamide0104 chemical sciences010404 medicinal & biomolecular chemistryRosmarinic acidComplementary and alternative medicinechemistryCinnamatesPolyphenolAnalytical Chemistry; Molecular Medicine; Pharmacology; 3003; Drug Discovery3003 Pharmaceutical Science; Complementary and Alternative Medicine2708 Dermatology; Organic ChemistryMolecular Medicineα-glucosidasemedicine.drug
researchProduct